Ovum Raises $4M Seed for AI Women's Health Data Platform

Melbourne-based health technology firm Ovum has successfully closed a $4 million Seed funding round, propelling its mission to revolutionize women's healthcare through advanced data analytics and artificial intelligence. The company's valuation now stands at $18 million following this significant capital injection.

The funding round was spearheaded by Admiralty Capital Group, with substantial contributions from a cohort of strategic investors including Antler, Giant Leap, Aviron Investments, Foggy Valley Aotearoa, Brisbane Angels, and Think & Grow. Demonstrating continued confidence, existing investor LaunchVic, soon to be integrated with Breakthrough Victoria, also participated through its Alice Anderson Fund, which champions female founders.

Ovum is leveraging this new capital to enhance its AI capabilities and expand its longitudinal data sets specifically tailored for women's health. The platform's AI meticulously gathers a comprehensive array of user data, encompassing symptoms, lifestyle choices, biometric readings, reproductive health stages, medication history, appointment logs, and medical reports. This detailed information is then processed to identify crucial health patterns, generate concise summaries, and formulate pertinent questions for physician consultations, empowering women to engage more effectively with their healthcare providers.

The company's growth trajectory since its August 2025 launch, following a $1.7 million pre-Seed raise in February 2025, has been remarkable. Ovum has achieved a consistent 30% month-on-month user expansion, surpassing 20,000 downloads. The platform has already aggregated over 57,000 health data insights and facilitated more than 107,000 AI-driven health conversations among users ranging from 15 to 84 years old. This widespread adoption underscores the critical need for dedicated women's health data solutions in the market.

Founded by Dr. Ariella Heffernan-Marks, a former medical student who experienced firsthand the challenges of navigating healthcare systems with insufficient data, Ovum aims to bridge the gap in equitable and actionable women's health information. "For too long, women have had to navigate healthcare systems that were not designed around their lived experiences or backed by sufficient female health data," stated Dr. Heffernan-Marks. "Ovum exists to help women better understand their bodies, advocate for themselves with confidence, and contribute to research that improves care for future generations." This personal drive fuels the company's commitment to transforming women's health outcomes.

The broader implications for the women's health technology sector are substantial. The global digital health market is projected to reach hundreds of billions of dollars in the coming years, with a significant portion dedicated to specialized areas like women's health. Ovum's focus on AI-driven insights addresses a critical unmet need, as historical medical research has often underrepresented female physiology. Partnerships with entities like private health insurer Medibank, fitness brands Fernwood Fitness and Sweat, and organizations such as Menopause Friendly Australia and Australian Red Cross Lifeblood further validate the platform's utility and potential impact across various health and productivity domains. The ongoing clinical trials with St George Hospital and the Royal Hospital for Women are expected to provide crucial data on AI's role in preventative women's healthcare.